75759
document
Levamisole versus placebo as an adjunct to primary therapy of laryngopharyngeal epidermoid carcinoma . Evaluation of the immune status . Twenty-four patients , with a biopsy-proven laryngeal or hypopharyngeal carcinoma , received as an adjunct to their primary treatment ( surgery and/or radiotherapy ) , levamisole ( 150 mg daily during three consecutive days , every fortnight ) or placebo , following a single-blind , but randomized method . At the end of the follow-up , an investigation of the immune status was done , and compared with that of a healthy control-group . It is concluded that the immunity is disturbed in patients with laryngo-pharyngeal cancer , but that this disturbance does not clearly correlate with the clinical state of the disease . Also , the immunological measures did not appear relevant to the significantly favourable effect of levamisole on the prognosis .
75760
Intervention_Psychological
Levamisole
75761
Intervention_Control
placebo
75762
Intervention_Pharmacological
levamisole
75763
Outcome_Physical
immune
75764
Outcome_Physical
immunity